These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Hemophilia and the human immunodeficiency virus. Slater PE Isr J Med Sci; 1991 Oct; 27(10):572-4. PubMed ID: 1955312 [No Abstract] [Full Text] [Related]
6. Commentary: non-HIV hypotheses must be studied more carefully. Duesberg P BMJ; 1996 Jan; 312(7025):210-1. PubMed ID: 8563583 [No Abstract] [Full Text] [Related]
7. [Factor VIII concentrates]. Faber JC Bull Soc Sci Med Grand Duche Luxemb; 1986; 123(2):27-9. PubMed ID: 3100076 [No Abstract] [Full Text] [Related]
8. Factor VIII replacement therapy. Issues and future prospects. Roberts HR Ann N Y Acad Sci; 1991; 614():106-13. PubMed ID: 1902638 [No Abstract] [Full Text] [Related]
9. Outbreaks of hepatitis A and emergence of new AIDS-associated agents: the need to add terminal 100 degrees C dry-heat sterilization to factor VIII and factor IX concentrates. Guillaume TA Vox Sang; 1993; 65(2):158. PubMed ID: 8212671 [No Abstract] [Full Text] [Related]
10. Surveillance and care of four Chinese hemophiliacs with human immunodeficiency virus (HIV) infection. Tang D; Qu G; Pang X; Lang Y; Liang Y; Yu Y; Zeng Y; Shao Y Chin Med Sci J; 1993 Mar; 8(1):41-3. PubMed ID: 8274721 [TBL] [Abstract][Full Text] [Related]
11. Three-year randomised study of high-purity or intermediate-purity factor VIII concentrates in symptom-free HIV-seropositive haemophiliacs: effects on immune status. Seremetis SV; Aledort LM; Bergman GE; Bona R; Bray G; Brettler D; Eyster ME; Kessler C; Lau TS; Lusher J Lancet; 1993 Sep; 342(8873):700-3. PubMed ID: 8103820 [TBL] [Abstract][Full Text] [Related]
12. Factor VIII concentrates in HIV-1-positive hemophiliacs--is pure better? Eichinger S; Pabinger I; Kyrle PA; Köller U; Kier P; Schneider B; Lechner K Haemostasis; 1992; 22(1):25-31. PubMed ID: 1521824 [TBL] [Abstract][Full Text] [Related]
13. [Cryoprecipitate should have preference over factor VIII concentrate in the treatment of patients with hemophilia A]. Kunst VA; Nováková IR; Haanen C Ned Tijdschr Geneeskd; 1989 Jun; 133(23):1163-6. PubMed ID: 2501689 [No Abstract] [Full Text] [Related]
14. High purity factor VIII concentrates for the treatment of HIV-positive patients with haemophilia. Sultan Y Blood Coagul Fibrinolysis; 1995 Jul; 6 Suppl 2():S80-1. PubMed ID: 7495974 [TBL] [Abstract][Full Text] [Related]
15. Immune status of asymptomatic HIV-infected hemophiliacs: randomized, prospective, two-year comparison of treatment with a high-purity or an intermediate-purity factor VIII concentrate. Mannucci PM; Gringeri A; de Biasi R; Baudo F; Morfini M; Ciavarella N Thromb Haemost; 1992 Mar; 67(3):310-3. PubMed ID: 1353642 [TBL] [Abstract][Full Text] [Related]
16. [Improvement in anti-hemophilic preparations and its problems. 4. Factor VIII preparation (RCG-5) with intermediate purity and potency]. Yoshioka A Rinsho Ketsueki; 1988 May; 29(5):649-54. PubMed ID: 3145996 [No Abstract] [Full Text] [Related]
17. Haemophilia, HIV infection, and blood transfusion in Belgium. Haemophilia Study Group. Acta Clin Belg; 1988; 43(2):95-100. PubMed ID: 3135685 [No Abstract] [Full Text] [Related]
18. Risks of immunodeficiency, AIDS, and death related to purity of factor VIII concentrate. Multicenter Hemophilia Cohort Study. Goedert JJ; Cohen AR; Kessler CM; Eichinger S; Seremetis SV; Rabkin CS; Yellin FJ; Rosenberg PS; Aledort LM Lancet; 1994 Sep; 344(8925):791-2. PubMed ID: 7916077 [TBL] [Abstract][Full Text] [Related]
19. Modulation of allogeneic cytotoxic activity by factor VIII or IX concentrates. Soria AG; Bouzas MB; Anselmo A; Ruibal-Ares BH Haematologica; 1991; 76(1):33-7. PubMed ID: 1829058 [TBL] [Abstract][Full Text] [Related]
20. The use of recombinant factor VIII in the management of hemophilia. Mannucci PM; Gringeri A Ric Clin Lab; 1991; 21(1):1-7. PubMed ID: 1907760 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]